| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thoracic Surgery | 60 | 2024 | 284 | 25.640 |
Why?
|
| Thoracic Surgical Procedures | 31 | 2024 | 259 | 11.630 |
Why?
|
| Social Media | 23 | 2021 | 208 | 9.680 |
Why?
|
| Surgeons | 31 | 2024 | 491 | 8.790 |
Why?
|
| Lung Neoplasms | 113 | 2024 | 12033 | 8.710 |
Why?
|
| Physicians, Women | 17 | 2024 | 103 | 7.920 |
Why?
|
| Metastasectomy | 12 | 2023 | 209 | 6.830 |
Why?
|
| Specialties, Surgical | 15 | 2022 | 135 | 6.730 |
Why?
|
| Pneumonectomy | 37 | 2023 | 862 | 6.660 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 63 | 2024 | 5574 | 6.280 |
Why?
|
| Internship and Residency | 29 | 2024 | 1452 | 6.120 |
Why?
|
| Education, Medical, Graduate | 20 | 2024 | 705 | 4.470 |
Why?
|
| Clinical Competence | 20 | 2023 | 1325 | 2.530 |
Why?
|
| Humans | 279 | 2024 | 270740 | 2.480 |
Why?
|
| Curriculum | 16 | 2021 | 919 | 2.440 |
Why?
|
| Authorship | 4 | 2022 | 48 | 2.340 |
Why?
|
| Esophagectomy | 22 | 2024 | 946 | 2.330 |
Why?
|
| Esophageal Neoplasms | 23 | 2024 | 3240 | 2.310 |
Why?
|
| Societies, Medical | 11 | 2024 | 1320 | 2.280 |
Why?
|
| Bibliometrics | 4 | 2022 | 64 | 2.210 |
Why?
|
| Colorectal Neoplasms | 12 | 2024 | 3707 | 2.080 |
Why?
|
| Thoracic Neoplasms | 7 | 2022 | 363 | 2.060 |
Why?
|
| Information Dissemination | 6 | 2020 | 268 | 1.990 |
Why?
|
| Lung Transplantation | 4 | 2024 | 383 | 1.980 |
Why?
|
| Attitude of Health Personnel | 8 | 2022 | 901 | 1.940 |
Why?
|
| Natural Language Processing | 3 | 2020 | 112 | 1.890 |
Why?
|
| Pandemics | 10 | 2021 | 1610 | 1.850 |
Why?
|
| General Surgery | 8 | 2021 | 333 | 1.830 |
Why?
|
| Periodicals as Topic | 8 | 2024 | 317 | 1.810 |
Why?
|
| Sexism | 7 | 2024 | 57 | 1.760 |
Why?
|
| Mentors | 7 | 2022 | 210 | 1.730 |
Why?
|
| Congresses as Topic | 5 | 2024 | 299 | 1.680 |
Why?
|
| Retrospective Studies | 84 | 2024 | 39890 | 1.630 |
Why?
|
| Internet | 6 | 2024 | 690 | 1.540 |
Why?
|
| Postoperative Complications | 20 | 2024 | 5681 | 1.470 |
Why?
|
| Radiosurgery | 8 | 2021 | 1383 | 1.440 |
Why?
|
| Behavior | 2 | 2021 | 100 | 1.390 |
Why?
|
| Adenocarcinoma | 17 | 2024 | 7914 | 1.390 |
Why?
|
| Health Care Sector | 2 | 2020 | 27 | 1.380 |
Why?
|
| Publishing | 3 | 2020 | 194 | 1.340 |
Why?
|
| Data Mining | 2 | 2020 | 83 | 1.330 |
Why?
|
| Operating Rooms | 2 | 2021 | 128 | 1.310 |
Why?
|
| Mentoring | 3 | 2020 | 105 | 1.300 |
Why?
|
| Female | 121 | 2024 | 148940 | 1.290 |
Why?
|
| Educational Measurement | 9 | 2023 | 397 | 1.180 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 625 | 1.130 |
Why?
|
| Neoplasm Staging | 35 | 2023 | 14012 | 1.120 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 700 | 1.120 |
Why?
|
| Nursing Staff, Hospital | 2 | 2021 | 74 | 1.120 |
Why?
|
| Male | 103 | 2024 | 128315 | 1.100 |
Why?
|
| Early Detection of Cancer | 5 | 2024 | 1340 | 1.060 |
Why?
|
| Neoplasm Recurrence, Local | 22 | 2024 | 10400 | 1.000 |
Why?
|
| Lung | 13 | 2024 | 3298 | 1.000 |
Why?
|
| Learning | 4 | 2020 | 431 | 0.990 |
Why?
|
| Patient Discharge | 4 | 2022 | 698 | 0.980 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2019 | 557 | 0.970 |
Why?
|
| Leadership | 4 | 2024 | 271 | 0.940 |
Why?
|
| Treatment Outcome | 44 | 2024 | 33737 | 0.920 |
Why?
|
| Lung Diseases | 3 | 2021 | 755 | 0.910 |
Why?
|
| Physicians | 2 | 2023 | 854 | 0.910 |
Why?
|
| Pulmonary Surgical Procedures | 2 | 2021 | 25 | 0.870 |
Why?
|
| Thoracic Surgery, Video-Assisted | 9 | 2023 | 211 | 0.860 |
Why?
|
| Medical Oncology | 6 | 2021 | 1465 | 0.860 |
Why?
|
| Phenanthrenes | 4 | 2010 | 43 | 0.860 |
Why?
|
| Empyema | 1 | 2023 | 37 | 0.850 |
Why?
|
| Empyema, Pleural | 1 | 2023 | 48 | 0.850 |
Why?
|
| Malus | 1 | 2022 | 8 | 0.840 |
Why?
|
| Parental Leave | 2 | 2021 | 13 | 0.830 |
Why?
|
| Diterpenes | 4 | 2010 | 115 | 0.830 |
Why?
|
| United States | 30 | 2024 | 15861 | 0.810 |
Why?
|
| Continuity of Patient Care | 2 | 2016 | 206 | 0.810 |
Why?
|
| Surveys and Questionnaires | 15 | 2023 | 5923 | 0.800 |
Why?
|
| Betacoronavirus | 5 | 2020 | 514 | 0.800 |
Why?
|
| Consolidation Chemotherapy | 2 | 2019 | 153 | 0.790 |
Why?
|
| Travel | 2 | 2023 | 203 | 0.780 |
Why?
|
| Middle Aged | 67 | 2024 | 90352 | 0.770 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 657 | 0.760 |
Why?
|
| Medicine | 1 | 2023 | 136 | 0.760 |
Why?
|
| Prognosis | 22 | 2024 | 22505 | 0.750 |
Why?
|
| Databases, Factual | 14 | 2023 | 2250 | 0.750 |
Why?
|
| Pain, Postoperative | 7 | 2021 | 662 | 0.740 |
Why?
|
| Medical Staff, Hospital | 1 | 2021 | 121 | 0.730 |
Why?
|
| Time Factors | 23 | 2024 | 13006 | 0.730 |
Why?
|
| Virtual Reality | 1 | 2021 | 35 | 0.730 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2024 | 7783 | 0.720 |
Why?
|
| Telecommunications | 1 | 2020 | 27 | 0.720 |
Why?
|
| Neoadjuvant Therapy | 15 | 2024 | 5231 | 0.720 |
Why?
|
| Organizational Culture | 1 | 2021 | 115 | 0.710 |
Why?
|
| Journal Impact Factor | 1 | 2020 | 34 | 0.700 |
Why?
|
| Coronavirus | 1 | 2020 | 37 | 0.700 |
Why?
|
| Women | 1 | 2020 | 24 | 0.700 |
Why?
|
| Aged | 61 | 2024 | 73333 | 0.700 |
Why?
|
| Specialty Boards | 1 | 2020 | 40 | 0.690 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2024 | 1158 | 0.670 |
Why?
|
| Scholarly Communication | 1 | 2019 | 19 | 0.670 |
Why?
|
| Ablation Techniques | 1 | 2021 | 149 | 0.660 |
Why?
|
| Forecasting | 2 | 2020 | 702 | 0.660 |
Why?
|
| Access to Information | 1 | 2019 | 52 | 0.660 |
Why?
|
| Funnel Chest | 2 | 2010 | 37 | 0.660 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2010 | 162 | 0.650 |
Why?
|
| Survival Rate | 18 | 2024 | 12541 | 0.650 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 99 | 0.650 |
Why?
|
| Specialization | 1 | 2020 | 128 | 0.650 |
Why?
|
| Noninvasive Ventilation | 1 | 2019 | 40 | 0.650 |
Why?
|
| Salvage Therapy | 7 | 2023 | 2123 | 0.640 |
Why?
|
| Surgical Oncology | 2 | 2020 | 211 | 0.640 |
Why?
|
| Women, Working | 1 | 2018 | 15 | 0.630 |
Why?
|
| Self Concept | 1 | 2020 | 198 | 0.620 |
Why?
|
| Social Networking | 1 | 2018 | 27 | 0.620 |
Why?
|
| Arteriosclerosis | 1 | 2019 | 178 | 0.620 |
Why?
|
| Academic Success | 1 | 2018 | 23 | 0.610 |
Why?
|
| Patient Readmission | 3 | 2021 | 572 | 0.610 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2010 | 605 | 0.600 |
Why?
|
| Patient Care Team | 3 | 2021 | 823 | 0.600 |
Why?
|
| Interdisciplinary Placement | 1 | 2017 | 5 | 0.600 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2019 | 94 | 0.600 |
Why?
|
| Pulmonary Sclerosing Hemangioma | 1 | 2017 | 5 | 0.590 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 861 | 0.590 |
Why?
|
| Ticlopidine | 1 | 2017 | 49 | 0.590 |
Why?
|
| Certification | 1 | 2018 | 107 | 0.590 |
Why?
|
| Risk Factors | 18 | 2024 | 17888 | 0.580 |
Why?
|
| Thoracotomy | 6 | 2023 | 218 | 0.580 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2017 | 51 | 0.580 |
Why?
|
| Length of Stay | 7 | 2024 | 2007 | 0.580 |
Why?
|
| Mesothelioma | 4 | 2018 | 558 | 0.570 |
Why?
|
| Social Perception | 1 | 2017 | 74 | 0.550 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2023 | 1402 | 0.520 |
Why?
|
| Esophageal Perforation | 1 | 2015 | 28 | 0.520 |
Why?
|
| Practice Management, Medical | 1 | 2015 | 19 | 0.520 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 272 | 0.510 |
Why?
|
| Fellowships and Scholarships | 2 | 2021 | 411 | 0.510 |
Why?
|
| Paclitaxel | 2 | 2015 | 2101 | 0.510 |
Why?
|
| Marketing of Health Services | 1 | 2015 | 33 | 0.510 |
Why?
|
| Pleural Neoplasms | 5 | 2021 | 485 | 0.500 |
Why?
|
| Truth Disclosure | 1 | 2017 | 179 | 0.500 |
Why?
|
| Pinocytosis | 1 | 2015 | 28 | 0.490 |
Why?
|
| Education | 2 | 2017 | 125 | 0.490 |
Why?
|
| Injury Severity Score | 1 | 2015 | 246 | 0.490 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 327 | 0.490 |
Why?
|
| Biomarkers, Tumor | 6 | 2021 | 10708 | 0.490 |
Why?
|
| Research Design | 2 | 2019 | 1569 | 0.480 |
Why?
|
| Osteopontin | 1 | 2015 | 145 | 0.480 |
Why?
|
| Gastroesophageal Reflux | 1 | 2018 | 368 | 0.480 |
Why?
|
| Needs Assessment | 4 | 2021 | 238 | 0.480 |
Why?
|
| Intergenerational Relations | 3 | 2021 | 15 | 0.470 |
Why?
|
| Neoplasms | 6 | 2023 | 15927 | 0.470 |
Why?
|
| Pylorus | 1 | 2014 | 31 | 0.470 |
Why?
|
| Cancer Survivors | 1 | 2021 | 742 | 0.460 |
Why?
|
| Follow-Up Studies | 17 | 2024 | 15218 | 0.460 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2024 | 1260 | 0.460 |
Why?
|
| Prospective Studies | 17 | 2024 | 13414 | 0.460 |
Why?
|
| Neuroblastoma | 2 | 2010 | 705 | 0.460 |
Why?
|
| Education, Medical | 2 | 2017 | 344 | 0.450 |
Why?
|
| Simulation Training | 3 | 2021 | 162 | 0.450 |
Why?
|
| Health Personnel | 1 | 2019 | 652 | 0.440 |
Why?
|
| Analgesics, Opioid | 5 | 2021 | 1468 | 0.440 |
Why?
|
| Sex Factors | 6 | 2024 | 2184 | 0.440 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2024 | 4000 | 0.440 |
Why?
|
| Education, Distance | 1 | 2014 | 100 | 0.420 |
Why?
|
| Foreign Bodies | 1 | 2014 | 160 | 0.420 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 831 | 0.410 |
Why?
|
| Laparoscopy | 3 | 2012 | 1302 | 0.410 |
Why?
|
| Hernia, Hiatal | 1 | 2012 | 67 | 0.400 |
Why?
|
| Duodenal Diseases | 1 | 2012 | 48 | 0.400 |
Why?
|
| Lymph Nodes | 4 | 2021 | 3077 | 0.400 |
Why?
|
| Surgical Instruments | 1 | 2012 | 141 | 0.400 |
Why?
|
| Patient Handoff | 1 | 2012 | 41 | 0.400 |
Why?
|
| Patient Selection | 9 | 2021 | 2025 | 0.400 |
Why?
|
| Bias | 2 | 2023 | 216 | 0.400 |
Why?
|
| Camping | 1 | 2011 | 16 | 0.400 |
Why?
|
| Fires | 1 | 2011 | 22 | 0.390 |
Why?
|
| Europe | 3 | 2017 | 658 | 0.390 |
Why?
|
| Intestinal Perforation | 1 | 2012 | 108 | 0.390 |
Why?
|
| Foreign-Body Migration | 1 | 2012 | 122 | 0.390 |
Why?
|
| Survival Analysis | 11 | 2021 | 9292 | 0.390 |
Why?
|
| ErbB Receptors | 4 | 2023 | 2375 | 0.380 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 730 | 0.380 |
Why?
|
| Vena Cava, Inferior | 1 | 2012 | 194 | 0.380 |
Why?
|
| Pain Management | 3 | 2021 | 712 | 0.380 |
Why?
|
| Biomedical Research | 1 | 2018 | 801 | 0.380 |
Why?
|
| Reoperation | 4 | 2019 | 1392 | 0.380 |
Why?
|
| Respiratory System Agents | 1 | 2011 | 9 | 0.370 |
Why?
|
| Esophagus | 1 | 2014 | 563 | 0.370 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2024 | 180 | 0.370 |
Why?
|
| Clinical Protocols | 3 | 2020 | 477 | 0.370 |
Why?
|
| Career Choice | 4 | 2021 | 210 | 0.370 |
Why?
|
| Burns | 1 | 2011 | 130 | 0.370 |
Why?
|
| Telephone | 3 | 2024 | 160 | 0.370 |
Why?
|
| Risk Assessment | 11 | 2021 | 6764 | 0.370 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 917 | 0.360 |
Why?
|
| Melanoma | 3 | 2023 | 5595 | 0.360 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 602 | 0.360 |
Why?
|
| Herniorrhaphy | 1 | 2012 | 179 | 0.360 |
Why?
|
| Esophagogastric Junction | 4 | 2023 | 557 | 0.360 |
Why?
|
| Preventive Health Services | 1 | 2011 | 67 | 0.350 |
Why?
|
| DNA Methylation | 3 | 2021 | 2765 | 0.350 |
Why?
|
| Mutation | 8 | 2023 | 15912 | 0.350 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 894 | 0.350 |
Why?
|
| Drug-Eluting Stents | 1 | 2011 | 77 | 0.350 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2011 | 124 | 0.350 |
Why?
|
| Head and Neck Neoplasms | 2 | 2023 | 4147 | 0.350 |
Why?
|
| Nanoparticles | 1 | 2015 | 585 | 0.350 |
Why?
|
| Chemoradiotherapy | 5 | 2023 | 2027 | 0.340 |
Why?
|
| Triage | 3 | 2020 | 255 | 0.340 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 104 | 0.340 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 1125 | 0.340 |
Why?
|
| Positron-Emission Tomography | 5 | 2024 | 2197 | 0.340 |
Why?
|
| Precancerous Conditions | 3 | 2021 | 1059 | 0.340 |
Why?
|
| Patient Simulation | 1 | 2009 | 47 | 0.330 |
Why?
|
| Radiopharmaceuticals | 4 | 2024 | 1341 | 0.330 |
Why?
|
| Pulmonary Emphysema | 1 | 2011 | 159 | 0.320 |
Why?
|
| Chemoradiotherapy, Adjuvant | 4 | 2021 | 562 | 0.320 |
Why?
|
| Educational Status | 2 | 2020 | 392 | 0.320 |
Why?
|
| Computer-Assisted Instruction | 1 | 2009 | 85 | 0.320 |
Why?
|
| Adult | 33 | 2024 | 82040 | 0.320 |
Why?
|
| Preoperative Care | 3 | 2019 | 1567 | 0.320 |
Why?
|
| Perioperative Care | 4 | 2024 | 447 | 0.320 |
Why?
|
| Attitude to Computers | 2 | 2019 | 61 | 0.320 |
Why?
|
| Multivariate Analysis | 6 | 2023 | 4328 | 0.310 |
Why?
|
| Anticarcinogenic Agents | 1 | 2011 | 368 | 0.310 |
Why?
|
| Bupivacaine | 2 | 2020 | 73 | 0.310 |
Why?
|
| Robotic Surgical Procedures | 3 | 2021 | 533 | 0.310 |
Why?
|
| Program Evaluation | 2 | 2022 | 603 | 0.310 |
Why?
|
| Cell Proliferation | 2 | 2019 | 7238 | 0.310 |
Why?
|
| Texas | 8 | 2020 | 6449 | 0.300 |
Why?
|
| Cohort Studies | 10 | 2020 | 9470 | 0.300 |
Why?
|
| Computer Simulation | 4 | 2021 | 1570 | 0.300 |
Why?
|
| Aspirin | 1 | 2011 | 375 | 0.300 |
Why?
|
| Margins of Excision | 2 | 2021 | 315 | 0.300 |
Why?
|
| Minnesota | 3 | 2012 | 126 | 0.290 |
Why?
|
| Gastrostomy | 1 | 2009 | 196 | 0.290 |
Why?
|
| Logistic Models | 5 | 2022 | 3444 | 0.290 |
Why?
|
| Bronchoscopy | 1 | 2011 | 481 | 0.290 |
Why?
|
| Incidence | 9 | 2021 | 5824 | 0.290 |
Why?
|
| Ipilimumab | 5 | 2024 | 764 | 0.290 |
Why?
|
| Disease-Free Survival | 10 | 2021 | 10265 | 0.280 |
Why?
|
| Smoking | 4 | 2023 | 2555 | 0.280 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2019 | 117 | 0.280 |
Why?
|
| Combined Modality Therapy | 6 | 2024 | 9039 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 2400 | 0.280 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 288 | 0.280 |
Why?
|
| Cancer Care Facilities | 4 | 2019 | 907 | 0.270 |
Why?
|
| Evidence-Based Medicine | 4 | 2021 | 1034 | 0.270 |
Why?
|
| Enteral Nutrition | 1 | 2009 | 347 | 0.270 |
Why?
|
| Opioid-Related Disorders | 3 | 2019 | 419 | 0.260 |
Why?
|
| Aged, 80 and over | 18 | 2021 | 30998 | 0.260 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2399 | 0.260 |
Why?
|
| Chest Tubes | 2 | 2024 | 119 | 0.260 |
Why?
|
| Metformin | 1 | 2010 | 393 | 0.260 |
Why?
|
| Testicular Hydrocele | 1 | 2005 | 6 | 0.260 |
Why?
|
| Patient Education as Topic | 2 | 2024 | 745 | 0.250 |
Why?
|
| Thoracic Wall | 2 | 2018 | 188 | 0.250 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 4492 | 0.250 |
Why?
|
| Fundoplication | 2 | 2018 | 70 | 0.250 |
Why?
|
| Hernia, Inguinal | 1 | 2005 | 51 | 0.240 |
Why?
|
| Neoplasm Invasiveness | 5 | 2019 | 4048 | 0.240 |
Why?
|
| Reproductive Rights | 1 | 2024 | 6 | 0.240 |
Why?
|
| Gastrectomy | 3 | 2023 | 476 | 0.240 |
Why?
|
| Vascular Surgical Procedures | 2 | 2021 | 619 | 0.240 |
Why?
|
| Mass Screening | 2 | 2023 | 1552 | 0.240 |
Why?
|
| Odds Ratio | 2 | 2021 | 2311 | 0.240 |
Why?
|
| Pediatrics | 2 | 2011 | 1186 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 9042 | 0.230 |
Why?
|
| Critical Care | 2 | 2013 | 796 | 0.230 |
Why?
|
| Apoptosis | 5 | 2011 | 7757 | 0.230 |
Why?
|
| Chylothorax | 1 | 2024 | 43 | 0.230 |
Why?
|
| Stomach Neoplasms | 3 | 2023 | 2331 | 0.230 |
Why?
|
| Consensus | 4 | 2021 | 1106 | 0.230 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 4960 | 0.220 |
Why?
|
| Propensity Score | 4 | 2021 | 772 | 0.220 |
Why?
|
| Elective Surgical Procedures | 1 | 2005 | 249 | 0.220 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2024 | 95 | 0.220 |
Why?
|
| Octreotide | 1 | 2024 | 131 | 0.220 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2021 | 1302 | 0.220 |
Why?
|
| Gastrointestinal Agents | 1 | 2024 | 118 | 0.220 |
Why?
|
| Academic Medical Centers | 3 | 2019 | 681 | 0.220 |
Why?
|
| Anastomotic Leak | 1 | 2024 | 83 | 0.220 |
Why?
|
| Transcription Factors | 2 | 2015 | 5438 | 0.220 |
Why?
|
| Reading | 1 | 2024 | 86 | 0.220 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2024 | 880 | 0.220 |
Why?
|
| Aftercare | 2 | 2022 | 252 | 0.220 |
Why?
|
| Comprehension | 1 | 2024 | 103 | 0.220 |
Why?
|
| Epoxy Compounds | 4 | 2010 | 57 | 0.220 |
Why?
|
| Immune System Diseases | 1 | 2023 | 65 | 0.220 |
Why?
|
| Neoplasms, Second Primary | 2 | 2024 | 1388 | 0.210 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 495 | 0.210 |
Why?
|
| Liquid Biopsy | 1 | 2023 | 164 | 0.210 |
Why?
|
| Publications | 1 | 2022 | 54 | 0.200 |
Why?
|
| Thyroid Diseases | 1 | 2022 | 85 | 0.200 |
Why?
|
| Personnel Selection | 1 | 2023 | 89 | 0.200 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 1032 | 0.200 |
Why?
|
| Genetic Testing | 1 | 2011 | 1696 | 0.200 |
Why?
|
| Cardiovascular Diseases | 2 | 2016 | 2224 | 0.200 |
Why?
|
| Personality | 1 | 2023 | 124 | 0.200 |
Why?
|
| Video Recording | 2 | 2021 | 281 | 0.200 |
Why?
|
| Pilot Projects | 3 | 2021 | 2828 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 16689 | 0.190 |
Why?
|
| Data Collection | 2 | 2019 | 608 | 0.190 |
Why?
|
| Mindfulness | 1 | 2022 | 56 | 0.190 |
Why?
|
| Intercostal Nerves | 2 | 2020 | 31 | 0.190 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2021 | 30 | 0.190 |
Why?
|
| Survivorship | 1 | 2021 | 116 | 0.190 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2021 | 8 | 0.190 |
Why?
|
| Minority Groups | 1 | 2023 | 328 | 0.190 |
Why?
|
| Accreditation | 2 | 2020 | 137 | 0.180 |
Why?
|
| Kirsten murine sarcoma virus | 1 | 2020 | 5 | 0.180 |
Why?
|
| Young Adult | 10 | 2020 | 22251 | 0.180 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 5149 | 0.180 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 6177 | 0.180 |
Why?
|
| Students | 1 | 2023 | 333 | 0.180 |
Why?
|
| Biology | 1 | 2021 | 76 | 0.180 |
Why?
|
| Men | 1 | 2020 | 8 | 0.180 |
Why?
|
| Burnout, Professional | 1 | 2024 | 224 | 0.180 |
Why?
|
| Carcinogenesis | 3 | 2021 | 1033 | 0.180 |
Why?
|
| Pleura | 1 | 2021 | 130 | 0.170 |
Why?
|
| Organizational Innovation | 1 | 2020 | 62 | 0.170 |
Why?
|
| Medicare | 2 | 2023 | 926 | 0.170 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 96 | 0.170 |
Why?
|
| Time | 1 | 2020 | 183 | 0.170 |
Why?
|
| Proportional Hazards Models | 7 | 2024 | 5101 | 0.170 |
Why?
|
| Anesthetics, Local | 2 | 2020 | 178 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2021 | 5593 | 0.170 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 135 | 0.170 |
Why?
|
| Group Processes | 1 | 2019 | 56 | 0.160 |
Why?
|
| Formative Feedback | 1 | 2019 | 33 | 0.160 |
Why?
|
| Public Health | 1 | 2021 | 296 | 0.160 |
Why?
|
| Guideline Adherence | 1 | 2023 | 632 | 0.160 |
Why?
|
| Equipment Failure Analysis | 1 | 2020 | 322 | 0.160 |
Why?
|
| Nerve Block | 2 | 2020 | 184 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2022 | 714 | 0.160 |
Why?
|
| Health Policy | 1 | 2021 | 278 | 0.160 |
Why?
|
| Awards and Prizes | 1 | 2020 | 86 | 0.160 |
Why?
|
| B7-H1 Antigen | 3 | 2023 | 1089 | 0.160 |
Why?
|
| Radiation Oncology | 2 | 2021 | 558 | 0.160 |
Why?
|
| Missouri | 1 | 2018 | 41 | 0.160 |
Why?
|
| Digestive System | 1 | 2019 | 121 | 0.160 |
Why?
|
| Microwaves | 1 | 2018 | 33 | 0.160 |
Why?
|
| Demography | 1 | 2020 | 433 | 0.160 |
Why?
|
| Medical Order Entry Systems | 1 | 2020 | 98 | 0.160 |
Why?
|
| Data Accuracy | 1 | 2018 | 45 | 0.160 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2011 | 333 | 0.160 |
Why?
|
| SEER Program | 2 | 2019 | 1047 | 0.160 |
Why?
|
| Quebec | 1 | 2018 | 20 | 0.160 |
Why?
|
| Dogs | 1 | 2020 | 1160 | 0.150 |
Why?
|
| Sarcoma | 2 | 2020 | 1839 | 0.150 |
Why?
|
| Cetuximab | 1 | 2020 | 474 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 165 | 0.150 |
Why?
|
| Neoplasm Metastasis | 4 | 2024 | 5315 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2021 | 714 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2024 | 6256 | 0.150 |
Why?
|
| Matched-Pair Analysis | 2 | 2021 | 100 | 0.150 |
Why?
|
| Adolescent | 10 | 2021 | 32767 | 0.150 |
Why?
|
| Caregivers | 1 | 2024 | 752 | 0.150 |
Why?
|
| Random Allocation | 1 | 2019 | 741 | 0.150 |
Why?
|
| Heparin | 1 | 2019 | 342 | 0.150 |
Why?
|
| Surgical Stapling | 1 | 2017 | 35 | 0.150 |
Why?
|
| Medicine in the Arts | 1 | 2017 | 11 | 0.150 |
Why?
|
| Lymphatic Metastasis | 4 | 2021 | 4963 | 0.150 |
Why?
|
| Work Schedule Tolerance | 1 | 2017 | 48 | 0.140 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2019 | 235 | 0.140 |
Why?
|
| Shift Work Schedule | 1 | 2017 | 19 | 0.140 |
Why?
|
| Treatment Failure | 2 | 2019 | 1430 | 0.140 |
Why?
|
| Quality Control | 1 | 2018 | 461 | 0.140 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 370 | 0.140 |
Why?
|
| Oncogenes | 1 | 2020 | 699 | 0.140 |
Why?
|
| Connective Tissue | 1 | 2016 | 37 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 512 | 0.140 |
Why?
|
| North America | 1 | 2017 | 338 | 0.140 |
Why?
|
| Caspase 3 | 4 | 2011 | 474 | 0.140 |
Why?
|
| Child | 8 | 2022 | 30559 | 0.140 |
Why?
|
| Exercise | 1 | 2024 | 1184 | 0.140 |
Why?
|
| Thoracoplasty | 1 | 2016 | 17 | 0.140 |
Why?
|
| Allografts | 1 | 2019 | 686 | 0.140 |
Why?
|
| Polytetrafluoroethylene | 1 | 2017 | 109 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 361 | 0.140 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 327 | 0.140 |
Why?
|
| Confidence Intervals | 1 | 2018 | 749 | 0.130 |
Why?
|
| Biopsy | 3 | 2020 | 3484 | 0.130 |
Why?
|
| Analgesia, Epidural | 1 | 2017 | 101 | 0.130 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 2017 | 92 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 205 | 0.130 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 984 | 0.130 |
Why?
|
| Peritoneal Neoplasms | 1 | 2023 | 859 | 0.130 |
Why?
|
| Anniversaries and Special Events | 1 | 2016 | 19 | 0.130 |
Why?
|
| Workload | 1 | 2017 | 194 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 2650 | 0.130 |
Why?
|
| Annexin A5 | 3 | 2011 | 74 | 0.130 |
Why?
|
| Acellular Dermis | 1 | 2017 | 101 | 0.130 |
Why?
|
| Diaphragm | 1 | 2017 | 187 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 2 | 2011 | 502 | 0.130 |
Why?
|
| Incidental Findings | 1 | 2017 | 282 | 0.130 |
Why?
|
| Neutrophils | 1 | 2020 | 873 | 0.130 |
Why?
|
| Cholangiocarcinoma | 2 | 2011 | 504 | 0.130 |
Why?
|
| Barrett Esophagus | 1 | 2021 | 559 | 0.130 |
Why?
|
| Patient Safety | 3 | 2020 | 613 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 3530 | 0.120 |
Why?
|
| Quality of Life | 3 | 2024 | 4761 | 0.120 |
Why?
|
| Transplant Recipients | 1 | 2018 | 337 | 0.120 |
Why?
|
| Consumer Health Information | 1 | 2015 | 49 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2019 | 727 | 0.120 |
Why?
|
| Smoking Cessation | 1 | 2021 | 776 | 0.120 |
Why?
|
| Models, Anatomic | 1 | 2016 | 146 | 0.120 |
Why?
|
| Thymus Neoplasms | 1 | 2020 | 416 | 0.120 |
Why?
|
| Evolution, Molecular | 1 | 2019 | 867 | 0.120 |
Why?
|
| Reproductive Behavior | 1 | 2014 | 10 | 0.120 |
Why?
|
| Surgical Mesh | 1 | 2016 | 212 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 3 | 2024 | 5257 | 0.120 |
Why?
|
| Birth Rate | 1 | 2014 | 18 | 0.120 |
Why?
|
| Circulating Tumor DNA | 1 | 2017 | 274 | 0.120 |
Why?
|
| Gestational Age | 2 | 2011 | 1173 | 0.120 |
Why?
|
| Problem-Based Learning | 2 | 2017 | 79 | 0.120 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2014 | 30 | 0.120 |
Why?
|
| Parents | 1 | 2021 | 1082 | 0.110 |
Why?
|
| Mediastinitis | 1 | 2013 | 22 | 0.110 |
Why?
|
| Case Management | 1 | 2013 | 37 | 0.110 |
Why?
|
| Anticoagulants | 1 | 2019 | 775 | 0.110 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 2357 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2016 | 419 | 0.110 |
Why?
|
| Feasibility Studies | 4 | 2021 | 2353 | 0.110 |
Why?
|
| Artificial Intelligence | 1 | 2018 | 425 | 0.110 |
Why?
|
| Communication | 1 | 2020 | 839 | 0.110 |
Why?
|
| Critical Illness | 2 | 2009 | 739 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2018 | 2315 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 306 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2016 | 544 | 0.110 |
Why?
|
| Tissue Array Analysis | 1 | 2015 | 757 | 0.110 |
Why?
|
| Disease Progression | 3 | 2021 | 6867 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2020 | 914 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2017 | 618 | 0.110 |
Why?
|
| Gastroplasty | 1 | 2012 | 21 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 761 | 0.100 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2012 | 12 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2021 | 1655 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2024 | 1828 | 0.100 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1234 | 0.100 |
Why?
|
| Transcriptome | 1 | 2021 | 1963 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 1958 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2020 | 1207 | 0.100 |
Why?
|
| Standard of Care | 1 | 2013 | 277 | 0.100 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 1894 | 0.100 |
Why?
|
| Cell Survival | 4 | 2011 | 3063 | 0.100 |
Why?
|
| Animals | 5 | 2020 | 61956 | 0.100 |
Why?
|
| Drainage | 1 | 2014 | 462 | 0.100 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2014 | 179 | 0.100 |
Why?
|
| Hospitalization | 2 | 2011 | 2167 | 0.090 |
Why?
|
| Test Taking Skills | 1 | 2011 | 5 | 0.090 |
Why?
|
| Family | 1 | 2015 | 783 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1840 | 0.090 |
Why?
|
| Heat-Shock Response | 1 | 2011 | 41 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 909 | 0.090 |
Why?
|
| Infant | 4 | 2018 | 13999 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2011 | 8699 | 0.090 |
Why?
|
| Fatigue | 1 | 2017 | 1275 | 0.090 |
Why?
|
| Apgar Score | 1 | 2011 | 55 | 0.090 |
Why?
|
| Suture Techniques | 1 | 2012 | 292 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2011 | 234 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 1235 | 0.090 |
Why?
|
| Cardiology | 1 | 2016 | 511 | 0.090 |
Why?
|
| Personality Assessment | 1 | 2010 | 116 | 0.090 |
Why?
|
| Device Removal | 1 | 2012 | 339 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2024 | 3557 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2023 | 505 | 0.090 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 2062 | 0.090 |
Why?
|
| Critical Pathways | 1 | 2011 | 160 | 0.080 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 210 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 3345 | 0.080 |
Why?
|
| Tumor Microenvironment | 4 | 2021 | 3035 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 4831 | 0.080 |
Why?
|
| Cell Line, Tumor | 5 | 2011 | 14849 | 0.080 |
Why?
|
| Program Development | 1 | 2010 | 259 | 0.080 |
Why?
|
| Birth Weight | 1 | 2011 | 355 | 0.080 |
Why?
|
| Caspase 9 | 1 | 2009 | 187 | 0.080 |
Why?
|
| Teaching | 1 | 2010 | 250 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 497 | 0.080 |
Why?
|
| Hyperplasia | 2 | 2021 | 564 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 2359 | 0.080 |
Why?
|
| Mice | 3 | 2019 | 35600 | 0.080 |
Why?
|
| Prosthesis Design | 1 | 2011 | 653 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 4795 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2010 | 827 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 1060 | 0.070 |
Why?
|
| Memory | 1 | 2011 | 445 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 14617 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2010 | 509 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2018 | 17061 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 3917 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 5162 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2010 | 1563 | 0.070 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 1553 | 0.070 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2011 | 386 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7381 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 464 | 0.060 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 533 | 0.060 |
Why?
|
| Sirolimus | 1 | 2010 | 831 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 599 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 2057 | 0.060 |
Why?
|
| Pain Measurement | 2 | 2020 | 1016 | 0.060 |
Why?
|
| Abortion, Legal | 1 | 2024 | 11 | 0.060 |
Why?
|
| Personhood | 1 | 2024 | 15 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 5056 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 1312 | 0.060 |
Why?
|
| Chyle | 1 | 2024 | 22 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 2196 | 0.060 |
Why?
|
| Comorbidity | 1 | 2011 | 2394 | 0.060 |
Why?
|
| DNA Copy Number Variations | 2 | 2021 | 1568 | 0.060 |
Why?
|
| Autophagy | 1 | 2010 | 911 | 0.060 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2011 | 641 | 0.060 |
Why?
|
| B-Lymphocytes | 2 | 2020 | 1424 | 0.060 |
Why?
|
| Editorial Policies | 1 | 2024 | 78 | 0.060 |
Why?
|
| Abortion, Induced | 1 | 2024 | 94 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2019 | 2033 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 4961 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2023 | 359 | 0.050 |
Why?
|
| Work-Life Balance | 1 | 2022 | 7 | 0.050 |
Why?
|
| Income | 1 | 2023 | 235 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2009 | 5759 | 0.050 |
Why?
|
| Social Stigma | 1 | 2022 | 74 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 4372 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2024 | 275 | 0.050 |
Why?
|
| Recurrence | 1 | 2010 | 4878 | 0.050 |
Why?
|
| Educational Personnel | 1 | 2020 | 3 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 275 | 0.050 |
Why?
|
| Videoconferencing | 1 | 2021 | 52 | 0.050 |
Why?
|
| Attention | 1 | 2022 | 282 | 0.040 |
Why?
|
| Neck | 1 | 2022 | 395 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2024 | 889 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2021 | 219 | 0.040 |
Why?
|
| Thymectomy | 1 | 2020 | 80 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2021 | 220 | 0.040 |
Why?
|
| Cytokines | 2 | 2020 | 2825 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2020 | 47 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2020 | 124 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 229 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 2022 | 489 | 0.040 |
Why?
|
| Clone Cells | 1 | 2021 | 591 | 0.040 |
Why?
|
| Occupational Health | 1 | 2020 | 90 | 0.040 |
Why?
|
| Registries | 2 | 2018 | 2211 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 484 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 1129 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2005 | 844 | 0.040 |
Why?
|
| Metaplasia | 1 | 2021 | 384 | 0.040 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2019 | 33 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2009 | 6390 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2021 | 518 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2021 | 247 | 0.040 |
Why?
|
| Anemia | 1 | 2005 | 728 | 0.040 |
Why?
|
| Esophagoscopy | 1 | 2021 | 310 | 0.040 |
Why?
|
| Heart Defects, Congenital | 1 | 2011 | 1795 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2021 | 338 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 311 | 0.040 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2019 | 78 | 0.040 |
Why?
|
| Self Report | 1 | 2023 | 796 | 0.040 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 67 | 0.040 |
Why?
|
| Pregnancy | 2 | 2024 | 8130 | 0.040 |
Why?
|
| Antigens, CD20 | 1 | 2019 | 207 | 0.040 |
Why?
|
| B7 Antigens | 1 | 2019 | 84 | 0.040 |
Why?
|
| Leucovorin | 1 | 2019 | 345 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 787 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 380 | 0.040 |
Why?
|
| Thoracoscopy | 1 | 2019 | 103 | 0.040 |
Why?
|
| Endoscopy, Digestive System | 1 | 2019 | 210 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 255 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 247 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 5002 | 0.040 |
Why?
|
| Nomograms | 1 | 2020 | 312 | 0.040 |
Why?
|
| Signal Transduction | 4 | 2021 | 12103 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2021 | 359 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 116 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 307 | 0.040 |
Why?
|
| Mediastinum | 1 | 2019 | 276 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2021 | 728 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2023 | 2345 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 675 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2020 | 639 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 453 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2017 | 218 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 896 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 738 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2021 | 699 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2019 | 704 | 0.030 |
Why?
|
| Proteomics | 1 | 2023 | 1427 | 0.030 |
Why?
|
| RNA Interference | 2 | 2011 | 1388 | 0.030 |
Why?
|
| Endosonography | 1 | 2019 | 551 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1020 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2016 | 149 | 0.030 |
Why?
|
| Glucose | 1 | 2021 | 1218 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 1049 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 1826 | 0.030 |
Why?
|
| Liposomes | 1 | 2017 | 704 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2019 | 1990 | 0.030 |
Why?
|
| Aorta | 1 | 2018 | 670 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 1246 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2021 | 1875 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 477 | 0.030 |
Why?
|
| Indoles | 1 | 2020 | 1028 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 681 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2018 | 626 | 0.030 |
Why?
|
| Pain | 1 | 2022 | 1694 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2019 | 1418 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 2035 | 0.030 |
Why?
|
| Debridement | 1 | 2013 | 121 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 1252 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 1933 | 0.030 |
Why?
|
| Cisplatin | 1 | 2020 | 2497 | 0.030 |
Why?
|
| Optical Imaging | 1 | 2013 | 158 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 1754 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 3949 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 2271 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 850 | 0.020 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2011 | 44 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5457 | 0.020 |
Why?
|
| Biomarkers | 1 | 2022 | 5051 | 0.020 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2010 | 40 | 0.020 |
Why?
|
| Social Responsibility | 1 | 2010 | 92 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 438 | 0.020 |
Why?
|
| Beclin-1 | 1 | 2010 | 88 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2010 | 123 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2010 | 135 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 5728 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 274 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 295 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2010 | 322 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 3844 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2019 | 4116 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 530 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 622 | 0.020 |
Why?
|
| Genomics | 1 | 2017 | 2835 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 1356 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5408 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 4644 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 3584 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1281 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 7895 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 2069 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 3187 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 7655 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2010 | 2928 | 0.010 |
Why?
|